Ad26.RSV.Pre-F

Adenovirus serotype 26-based Respiratory Syncytial Virus Pre-Fusion vaccine · Janssen Vaccines & Prevention B.V.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ad26.RSV.Pre-F, covering 2022-11-30 to 2022-11-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age [Phase 1, Phase 2]

See pricing